Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide versus placebo in high-risk non-metastatic castration-resistant prostate cancer
NL-OMON54510Phase 3Recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Dec 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apalutamide in prostate cancer (PCa), sponsored by Aragon Pharmaceuticals. Started Dec 2014; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON54510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54510.